FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / Tirzepatide
COA ↓
Product
COA Doc
SYN-2622
99.1% Purity SYN-2622 Research Grade HPLC Verified

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist · Research Grade

Select Strength — 15mg

$115.00
C₂₂₅H₃₄₈N₄₈O₆₈ MW: 4813.47 g/mol CAS: 2023788-19-2
Available on Backorder
1
Backordered — orders ship within 5–10 business days in the sequence received.

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
HPLC Purity
Lot Number SYN-2622-TIRZ
Test Date
Labeled 98.0%
Actual 98.0%
HPLC Purity
Lot Number SYN-2521-TIRZ
Test Date
Labeled 98.0%
Actual 98.4%

Research Data

KEY FINDINGS

🧬
22.5%
Body Weight Reduction (SURMOUNT-1)
Phase III SURMOUNT-1 at 72 weeks — the most effective approved weight-loss drug
🔬
FDA
Approved (Mounjaro/Zepbound)
FDA-approved 2022 (Mounjaro for T2D) and 2023 (Zepbound for obesity)
✅
98.0%
HPLC-Verified Purity
Current batch SYN-2622, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

📉 Phase III SURMOUNT-1 Trial

22.5% Weight Loss — Most Effective Approved Drug in History

Jastreboff et al. published SURMOUNT-1 in NEJM 2022, demonstrating tirzepatide 15mg achieved 22.5% mean body weight reduction at 72 weeks — the greatest weight loss ever demonstrated in a Phase III pharmaceutical trial. FDA approved Zepbound (tirzepatide) for obesity in November 2023.

Tirzepatide 15mg −22.5%
Semaglutide 2.4mg −14.9%
Placebo −2.4%
🔬 22.5% weight reduction — the Phase III record surpassed only by Retatrutide (Phase II, 24.2%) in subsequent trials.
PMID 35658024 — NEJM (SURMOUNT-1)
22.5 %
SURMOUNT-1 — 22.5% Weight Reduction at 72 Weeks

Tirzepatide (Mounjaro/Zepbound) is the first dual GIP/GLP-1 receptor agonist approved for both type 2 diabetes and obesity. SURMOUNT-1 Phase III trial demonstrated 22.5% mean body weight reduction at 72 weeks — the greatest weight loss ever demonstrated in a Phase III pharmaceutical trial at time of publication.

SURMOUNT-1 Weight Loss — Tirzepatide vs. Placebo at 72 Weeks
Tirzepatide 15mg −22.5%
Tirzepatide 10mg −21.4%
Tirzepatide 5mg −16.0%
Placebo −2.4%
Source: Jastreboff AM et al., NEJM, 2022

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2622-TIRZ
Specification Value
CAS Number 2023788-19-2
Molecular Formula C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight 4813.47 g/mol
Purity (HPLC) 99.1%
Appearance White lyophilised powder
Solubility Soluble in water (1 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

Phase III SURMOUNT-1 Trial — NEJM, 2022

22.5 %

Mean Body Weight Reduction at 72 Weeks (15mg dose, SURMOUNT-1)

Tirzepatide 15mg −22.5%
Semaglutide 2.4mg (STEP-1) −14.9%
Placebo −2.4%

Comparative Activity Profile

Tirzepatide Semaglutide
🛡️

In Vitro Safety Data

SAFETY PROFILE

Tirzepatide carries the full Phase III safety dataset from SURMOUNT-1/2/3/4 and SURPASS trials (combined N>10,000). GI adverse events are the primary tolerability concern, consistent with the GLP-1 mechanism component. The GIP component appears to mitigate nausea severity vs. GLP-1 monotherapy.

Observed Adverse Indicators

37%

Nausea (any grade)

moderate
21%

Diarrhoea

low
16%

Vomiting

moderate
5%

Serious adverse events

low
4%

Discontinuation due to AEs

low

⚠️ Theoretical Concern

Research Use & Regulatory Context

Tirzepatide (Mounjaro/Zepbound) holds full FDA approval for T2D and obesity with an established Phase III safety database. All in vitro observations must remain within laboratory research parameters.

  • FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for obesity) — most comprehensive approval dataset of any GLP-1 class agent
  • GI adverse events dose-dependent and typically transient; peak incidence during dose-escalation phase
  • Pancreatitis signal monitored per class labelling — incidence not elevated vs. GLP-1 monotherapy in Phase III
  • For in vitro laboratory research use only — not for human or veterinary administration
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

New England Journal of Medicine
Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1
2022 Jastreboff AM et al.
PMID 35658024 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$65.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →